http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2767878-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_598513b56c015a91156bee4e430b1b05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4995 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5386 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5386 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4995 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e56c49aa980f22b7626a86b275600db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60773a3b3d9187ff1441f7fdc0bfc5d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86fd4d56ed4f2b3d2475a29db3b39231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1003edbc49ebf9fcd3c738d60255b266 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d4479b106c3965c76006ffdab3deca2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_334daf1028400968746e52fa686aad70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4be8e0d9be4394f265621161c1d55654 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d96dfaad9a8626584a4677836636d42 |
| publicationDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2767878-C2 |
| titleOfInvention | Novel compound and its pharmacologically acceptable salt |
| abstract | FIELD: pharmaceutics.SUBSTANCE: invention relates to a compound of general formula (1), or a pharmacologically acceptable salt thereof, where R3denotes a hydrogen atom, R4denotes 5–6-membered monocyclic heterocyclic group, containing from 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, selected from thiazole (optionally substituted with methyl), furan, pyrazole (optionally substituted with methyl), pyridine (optionally substituted with fluorine), oxazole, isothiazole, 1,2,4-thiadiazole and pyrimidine; X denotes a group described by the following formula: -CH2-, -CH2-CH2-, -CH2-CH2-CH2- or -CH2-O-CH2-; Z denotes a hydrogen atom or a hydroxy group; R1is selected from (i) a hydrogen atom, a halogen atom, a hydroxy group, a carboxy group, a cyano group, a sulfamoyl group and an aminocarbonyl group; and (ii) a C1-6alkyl group; C3-7cycloalkyl group; thiazole; tetrahydrofuran, thiomorpholine and piperidine; C1-6acylamino groups; C1-6alkyloxy groups; C1-6alkyloxy-C1-6alkyl group; C3-7cycloalkyloxy group; 6-member monocyclic aromatic heterocyclyloxy group containing 1 heteroatom selected from an oxygen atom; C1-6alkylthio group; C1-6alkylsulphonyl group; C1-6alkylsulphinyl group; mono-C1-6alkylsulfamoyl group, di-C1-6alkylsulfamoyl group; di-C1-6alkylsulfamoyl group, in which two C1-6alkyl groups can form a pyrrolidin-1-yl group or a morpholine group with an adjacent nitrogen atom; C1-6alkylcarbonyl group and C1-6alkyloxycarbonyl group; each of which is optionally substituted with 1–6 substitutes; and R2is selected from (i) a hydrogen atom, a halogen atom, a hydroxygroup, a carboxygroup, a cyanogroup, a sulfamoyl group and an aminocarbonyl group; and (ii) a C1-6alkyl group; C1-6acylamino groups; C1-6alkyloxy groups; C2-6alkenyloxy groups; C1-6alkyloxy-C1-6alkyl group; C3-7cycloalkyloxy group; C1-6alkylthio group; C1-6alkylsulphonyl group; C1-6alkylsulphinyl group; mono-C1-6alkylsulfamoyl group; di-C1-6alkylsulfamoyl group; C1-6alkylcarbonyl group and C1-6alkyloxycarbonyl group. Invention also relates to a pharmaceutical composition having PDE4 inhibitory activity, comprising an effective amount of at least one component selected from a group consisting of a compound of formula I and a pharmacologically acceptable salt thereof as an active ingredient, and at least one component selected from a group consisting of an inert filler, a disintegrant, a binder, a lubricant and a dye.EFFECT: novel compound and a pharmacologically acceptable salt thereof are disclosed.6 cl, 69 tbl, 421 ex |
| priorityDate | 2016-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2633.